1stOncology™: Cancer Intelligence Service – Page 5739 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022

On October 6, 2022 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new clinical data from its dual combination COM701/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), taking place between 10-12 November 2022, Boston, MA (Press release, Compugen, OCT 6, 2022, View Source [SID1234621808]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Oral presentation details:

Title: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases

Abstract Number: 659

Session Title: Clinical Development of Novel Checkpoint Inhibitors

Session Date Thursday, November 10, 2022, 6:45pm ET

Title: PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion

Abstract Number: 504

Session Title: Next Generation Checkpoint Blockade: Mechanisms of Action

Session Date: Friday, November 11, 2022, 5:20pm ET

Compugen’s presentations will be available on the publications section of Compugen’s website, www.cgen.com following presentation.

Cytovia Therapeutics To Present New Data on TALEN® Gene-Edited iNK Cells and GPC3-Targeted Flex-NK™ Cell Engagers at 2022 SITC Annual Meeting

On October 6, 2022 Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, reported that it will be presenting new preclinical data for its TALEN gene-edited, iPSC-derived NK cells and GPC3-targeted Flex-NK cell engager antibodies at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting (SITC 2022) taking place in Boston, MA, and virtually November 8-12th, 2022 (Press release, Cytovia Therapeutics, OCT 6, 2022, View Source [SID1234621807]).

Leidos Schedules Third Quarter 2022 Earnings Conference Call for November 1, 2022 at 8 a.m. (ET)

On October 6, 2022 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology company, reported that has scheduled a conference call for Tuesday, Nov. 1, 2022, at 8 a.m. (ET) its third quarter 2022 financial results for the period ending Sept. 30, 2022 (Press release, Leidos, OCT 6, 2022, View Source [SID1234621806]). The company plans to issue its quarterly earnings press release before the conference call on Nov. 1, 2022.

The company offers a live and replay audio broadcast of the conference call with corresponding press release, presentation materials, and supplemental information at View Source

An archived version of the webcast will be available on the Leidos Investor Relations website at View Source

New Publication Validates Performance of Natera’s Signatera™ MRD Test in Ovarian Cancer

On October 6, 2022 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported the publication of a manuscript in Gynecologic Oncology, found here, validating the performance of its personalized molecular residual disease (MRD) test, Signatera, in epithelial ovarian cancer (EOC) (Press release, Natera, OCT 6, 2022, View Source [SID1234621804]). This study adds to the growing library of over 30 published clinical studies incorporating Signatera technology.

The blinded, multi-site study analyzed 163 plasma samples from 69 patients with Stage I-IV disease across a range of histologies, including high-grade serous (54%), endometrioid (13%), clear cell (13%) and other (20%). Test performance was evaluated at multiple time points: pre-surgery, post-surgery prior to adjuvant treatment, and longitudinally every 3 months for up to 40 months after the completion of definitive therapy. With longitudinal testing, recurrence was detected with 100% sensitivity, 100% specificity, and an average lead time of 10 months ahead of imaging compared to 1 month for CA-125.

"Ovarian cancer is an aggressive disease with poor survival, especially in advanced stages. This study suggests that ctDNA analysis can provide clinicians with invaluable information regarding an individual patient’s prognosis," said Dr. Minetta C. Liu, Natera’s chief medical officer of oncology. "Furthermore, high sensitivity and a significant lead time in detecting recurrence before both CA-125 and surveillance imaging could elicit a meaningful impact on patient outcomes by informing timely treatment decisions for personalized disease management."

EOC is the most lethal gynecologic cancer worldwide.1 In the U.S., it is the fifth most common cancer type in women.2 The 5-year survival rate decreases significantly as stage increases3 and the majority of patients will recur, even when achieving complete remission with primary treatment.4

About Signatera
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The test is available for both clinical and research use, and has been granted three Breakthrough Device Designations by the FDA for multiple cancer types and indications. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor. This maximizes Signatera’s accuracy for detecting the presence or absence of residual disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and assess how much cancer is left in the body, to identify recurrence earlier and to help optimize treatment decisions.

AIkido Share Repurchase Continues

On October 6, 2022 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported an update on the Company’s share repurchase program (the "Share Repurchase Program") authorized by the Company’s Board of Directors on January 21, 2022 (Press release, AIkido Pharma, OCT 6, 2022, View Source [SID1234621803]).

The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share.

Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b -18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, including blackout period restrictions.